Amycretin vs Wegovy: Should You Wait for the Next-Gen Drug?

If you’re choosing between starting Wegovy now and holding out for amycretin, here’s the honest framing. Wegovy is FDA approved, widely available, and backed by years of data. Amycretin is Novo Nordisk’s investigational follow-up, still years from any approval, that aims for stronger results and adds a pill option. They’re related (both use the GLP-1 hormone pathway, and amycretin adds amylin), but only one is something you can start today. For most people, waiting for amycretin isn’t the practical choice, because Wegovy already works and is available now.

What Is Wegovy?

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly GLP-1 injection FDA approved in 2021 for chronic weight management. It curbs appetite and slows stomach emptying, helping people eat less. In its main trial (STEP 1), Wegovy produced about 15% average weight loss over 68 weeks, and two-year data showed that loss was largely maintained at around 15% at 104 weeks for those who kept taking it.

Beyond weight, semaglutide has a deep evidence base, including a large cardiovascular outcomes trial (SELECT) showing it reduced the risk of heart events in people with obesity and established heart disease. That kind of long-term, proven track record is exactly what amycretin doesn’t have yet.

What Is Amycretin?

Amycretin is Novo Nordisk’s investigational next-generation drug. It activates two appetite targets in a single molecule (GLP-1, the same pathway as Wegovy, plus amylin, a fullness hormone), and it’s being developed as both a weekly injection and a daily pill.

The early results are encouraging: in a Phase 1b/2a obesity study, injectable amycretin produced estimated weight loss of about 22% at 36 weeks on the top dose, and an oral version showed meaningful loss too. In late 2025, Phase 2 results in people with type 2 diabetes showed up to roughly 14.5% weight loss with the injection and 10.1% with the pill. Both forms are advancing to Phase 3 in 2026, which means amycretin is still years from a possible approval.

Amycretin vs Wegovy at a Glance

Should You Wait for Amycretin?

The case people make for waiting

Amycretin’s early numbers look higher than Wegovy’s, and the prospect of an effective daily pill is appealing for anyone who dislikes injections. If those results hold up in Phase 3, amycretin could eventually be a stronger option.

Why waiting usually doesn’t make sense

Here’s the reality check. Amycretin is just entering Phase 3 in 2026, so even in a best case it’s likely 2028 or later before it could be approved and available. Its strongest weight loss figure comes from a small, early study, so it carries real uncertainty. Meanwhile, Wegovy works now and has long-term safety and outcomes data behind it. Weight loss benefits accumulate while you wait, not after, and if amycretin (or another new drug) proves better down the line, switching is straightforward. For most people, the math favors starting an effective, available treatment rather than delaying years for an unproven one.

A note on the pill

Amycretin’s oral form is its most distinctive feature, but it’s worth keeping in perspective. The pill’s early results trail amycretin’s own injection, and oral GLP-1 options are a crowded, fast-moving area. An approved daily pill is likely coming to this category, but it isn’t here yet, and Wegovy’s injection is a well-understood, once-weekly routine that many people manage easily.

Why Amycretin Isn’t Available Yet

Amycretin is investigational and still in mid-stage development, so it can’t be prescribed, and there’s no legal compounded version (compounding applies to approved drugs). Any “research-use-only” peptide sold online as amycretin lacks pharmacy oversight on purity, sterility, and dosing, and isn’t a safe or legal substitute. The trial doses mentioned here reflect what researchers used under supervision, not a plan to follow yourself.

Starting Treatment Now

If you’re ready to make progress, Wegovy is one of several effective options available today, and a licensed provider can help you decide whether semaglutide or another medication best fits your health history and goals. Waiting for the next molecule means putting off benefits you could be getting now.

To find out whether treatment is right for you, TrimRx’s intake quiz is a straightforward first step.

This article is for general educational purposes only and is not medical advice. Amycretin is an investigational drug that has not been approved by the FDA and is not available by prescription or through TrimRx; any product sold online as amycretin outside a clinical trial is unregulated and potentially unsafe. Wegovy is FDA approved but carries its own risks and is not appropriate for everyone. Weight loss figures reflect clinical trial findings and are not guarantees of individual results. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment, and never attempt to self-source or self-administer an investigational medication.